Novartis Sues Apotex To Block Generic Exelon

Law360, New York (October 27, 2010, 3:19 PM EDT) -- Novartis AG has slapped Apotex Inc. with a patent infringement lawsuit in an effort to keep the Toronto-based drugmaker from introducing a generic version of the dementia treatment Exelon.

Novartis filed its complaint Tuesday in the U.S. District Court for the District of Delaware, following Apotex's filing of an abbreviated new drug application with the U.S. Food and Drug Administration seeking approval for a copycat version of the dementia drug.

The complaint asserts that Apotex's ANDA infringes two patents, U.S. Patent Numbers 4,948,807 and 5,602,176. The...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.